Dexcom recently became the first medical device company to embed generative AI into a continuous glucose monitor. Adding generative AI to the company’s Stelo glucose monitor will give users more personalized recommendations about how to improve their metabolic health, said Dexcom COO Jake Leach.
This week at HLTH, Dexcom COO Jake Leach discussed Stelo, his company's new product. Stelo is an over-the-counter continuous glucose monitor meant for all adults who don't take insulin.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
In July, Dexcom got FDA clearance to allow third parties to access its CGM data. To start, it is integrating with Garmin’s wearable devices.
The company recently published new results on its MOBILE study, which found that CGM use increased time in range for people with Type 2 diabetes. New data shows people who stopped using a CGM saw time in range decrease.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
In a wide-ranging interview, Dexcom’s CEO shared more about the company’s push to prove its continuous glucose monitor can be used both for patients with Type 1 and Type 2 diabetes, and how the device-maker is handling a growing number of competitors.
Dexcom launched its first venture fund. The company, which makes continuous glucose monitors, plans to invest in glucose sensing technologies and metabolic monitoring.
The company is rolling out Level2, a digital health program for patients with type 2 diabetes. It uses wearable devices and coaches to help users manage their health.
Abbott Laboratories received FDA clearance for its newest continuous glucose monitor, the FreeStyle Libre 2. The product is one of many in a growing market for CGMs.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
In an interview at the J.P. Morgan Healthcare Conference in San Francisco earlier this week, the CEO of Dexcom relayed a strong desire to sell CGM systems directly to the consumers with possible pilots this year.
Livongo and Dexcom struck a partnership on Monday that would combine Dexcom’s continuous glucose monitors with Livongo’s software. At the StartUp Health Conference, Livongo President Jennifer Schneider said its work with Dexcom would create a new stream of data for both companies.
The money will help the company launch its first insulin-management product by the end of this year, which is likely to face stiff competition from larger rivals.
Medical device maker Dexcom is partnering with Livongo such that users of Livongo that have diabetes and use Dexcom's continuous glucose monitoring system can sync their data on the Livongo platform.
Tandem Diabetes’ technology will create a new approval pathway for predictive dosing software that can be used with other devices.